Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3Gynecologic 2Thoracic 1Sarcoma 1Genitourinary 1Breast 1

Conditions

Pituitary Diseases 3Pituitary ACTH Hypersecretion 3Cushing Syndrome 3ACTH Syndrome, Ectopic 3Hirsutism 2Choristoma 2Adrenal Cortex Neoplasms 2

Interventions

Everolimus 23pasireotide 14lutetium Lu 177 dotatate 10Octreotide 10lanreotide 9surufatinib 8Carboplatin 8Paclitaxel 7pembrolizumab 5amino-acid, glucose, and electrolyte solution 5Thyrotropin Alfa 5Sunitinib 5Nivolumab 5Injections 53-Iodobenzylguanidine 5relacorilant 4fosbretabulin 4Temozolomide 4Fulvestrant 4Etoposide 4Data Collection 4Cisplatin 4vandetanib 3selpercatinib 3dabrafenib 3anlotinib 3Mifepristone 3Lutetium-177 3Lutetium 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Mifepristone × Endocrine × Clear all
NCT00936741 2014-04-02

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Corcept Therapeutics

Phase 3 Completed
30 enrolled 8 charts
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Choristoma, Cushing Syndrome, Hirsutism, Pituitary Diseases, Pituitary ACTH Hypersecretion

NCT01371565 2014-03-18

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Corcept Therapeutics

Phase 3 Completed
4 enrolled 7 charts
Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Pituitary Diseases, Pituitary ACTH Hypersecretion

NCT00569582 2013-08-22

SEISMIC

Corcept Therapeutics

Phase 3 Completed
50 enrolled 8 charts
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Choristoma, Cushing Syndrome, Hirsutism, Pituitary Diseases, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡